Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2023-186318

Published: 2023

Journal Articles

Diagnostic Utility of Comprehensive RNA-Seq Analysis in Adult B-ALL

Noushin Farnoud, Konstantinos Liosis, Daniel Leongamornlert, Jesús Gutiérrez-Abril, Juan E. Arango Ossa, Gunes Gundem, Anu Amallraja, Dylan Domenico, Joseph McCarter, Amy A Kirkwood, Laura Clifton-Hadley, Bela Patel Wrench, Anthony Moorman, Adele Kay Fielding, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2023-190519

Published: 2023

Journal Articles

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Kushani Ediriwickrema, Neil K Rabin, Shirley D'Sa, Graham Jackson, Peter Hoskin, Eve Gallop-Evans, Patricia Diez, Catherine Parbutt, Andre Lopes, Sevasti Galani, Laura Clifton-Hadley, Darren Edwards, Husne Timur Tezver, Ruth M. de Tute, Andrew Bates, Roger G Owen

Blood (2022) 140 (Supplement 1): 12626–12627.

https://doi.org/10.1182/blood-2022-158528

Published: 2022

Journal Articles

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Blood (2022) 140 (Supplement 1): 10191–10192.

https://doi.org/10.1182/blood-2022-166344

Published: 2022

Journal Articles

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Blood (2022) 140 (Supplement 1): 6356–6357.

https://doi.org/10.1182/blood-2022-165985

Published: 2022

Journal Articles

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Bela Patel Wrench, Amy A. Kirkwood, Krisztina Zuborne Alapi, Laura Clifton-Hadley, SooWah Lee, David I. Marks, Anthony V. Moorman, Nicholas J. Morley, Pip Patrick, Zaynab Rana, Clare J. Rowntree, John A. Snowden, Adele K. Fielding

Blood (2022) 140 (Supplement 1): 6125–6126.

https://doi.org/10.1182/blood-2022-159958

Published: 2022

Journal Articles

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Blood (2022) 140 (Supplement 1): 10106–10107.

https://doi.org/10.1182/blood-2022-169882

Published: 2022

Journal Articles

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Jaimal Kothari, Toby A. Eyre, Ali Rismani, Helen McCarthy, Angela Collins, David John Lewis, Suzanne O Arulogun, William Wilson, Laura Clifton-Hadley, Darren Edwards, Kushani Ediriwickrema, Rebecca Auer, Guy Pratt, Ruth M. de Tute, Roger G Owen, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3624–3626.

https://doi.org/10.1182/blood-2022-167158

Published: 2022

Journal Articles

Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

Michael Northend, William Wilson, Laura Clifton-Hadley, Zaynab Rana, Tanya-Louise Martin, Moya Young, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoglu, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna

Blood (2022) 140 (Supplement 1): 1456–1458.

https://doi.org/10.1182/blood-2022-156790

Published: 2022

Journal Articles

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Stephen Booth, Eliza Hawkes, Amy A Kirkwood, Sally F Barrington, Patrick G. Medd, Pamela McKay, Ruth Pettengell, Sunil Iyengar, Fiona Miall, John Radford, Cathy Burton, Amit Sud, Nimish Shah, Andrew M Scott, Arzhang Ardavan, Michael Northend, Laura Clifton-Hadley, Richard Jenner, Graham P. Collins

Blood (2021) 138 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2021-145189

Published: 2021

Journal Articles

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Blood (2021) 138 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2021-150177

Published: 2021

Journal Articles

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Blood (2021) 138 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2021-147771

Published: 2021

Journal Articles

First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)

Clare J Rowntree, Amy A Kirkwood, Laura Clifton-Hadley, Nadine Farah, Marc R. Mansour, Jiaull Hussain, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Pip Patrick, Bela Wrench, Adele K. Fielding

Blood (2021) 138 (Supplement 1): 366.

https://doi.org/10.1182/blood-2021-152355

Published: 2021

Journal Articles

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137768

Published: 2020

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Anthony V. Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Thomas Creasey, MBBS, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Christine J. Harrison, PhD FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 288.

https://doi.org/10.1182/blood-2019-123642

Published: 2019

Journal Articles

Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial

Daniel A. Leongamornlert, PhD, Emilio Barretta, Soo Lee, Thomas Creasey, MBBS, Rachel J. Mitchell, MSc, Amy A. Kirkwood, MSc, Laura Clifton-Hadley, PhDBSc, Pip Patrick, PhDMSc,MA, Peter J Campbell, Bela Wrench, MBBS, MD MRCP, FRCPath, Anthony V. Moorman, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 2743.

https://doi.org/10.1182/blood-2019-125723

Published: 2019

Journal Articles

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Thomas Creasey, MBBS, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Nicholas J. Morley, John A Snowden, BSc (Hons), MBChB, MD FRCP, FRCPath, Christine J. Harrison, PhD FRCPath, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman

Blood (2019) 134 (Supplement_1): 2746.

https://doi.org/10.1182/blood-2019-124395

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

NARROW

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Diagnostic Utility of Comprehensive RNA-Seq Analysis in Adult B-ALL

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only